MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Name
nihms827549.pdf
Size
2.43 MB
Format
Adobe PDF
Checksum (MD5)
f8ad88ca8dd989b0b486eceb3f851591
Author(s)
Han, Sangyoon
Jonas, Oliver
Oudin, Madeleine Julie
Barbier, Lucie
Schafer, Claudia
Kosciuk, Tatsiana
Miller, Miles Aaron
Lauffenburger, Douglas A
Gertler, Frank
Date Issued
November 2016
Journal
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research (AACR)
Citation
Oudin, Madeleine J. et al. “MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics 16, 1 (November 2016): 143–155 © 2016 American Association for Cancer Research
Version
Author's final manuscript
Abstract
Taxane therapy remains the standard of care for triple-negative breast cancer. However, high frequencies of recurrence and progression in treated patients indicate that metastatic breast cancer cells can acquire resistance to this drug. The actin regulatory protein MENA and particularly its invasive isoform, MENAINV , are established drivers of metastasis. MENAINV expression is significantly correlated with metastasis and poor outcome in human patients with breast cancer. We investigated whether MENA isoforms might play a role in driving resistance to chemotherapeutics. We find that both MENA and MENAINV confer resistance to the taxane paclitaxel, but not to the widely used DNA-damaging agents doxorubicin or cisplatin. Furthermore, paclitaxel treatment does not attenuate growth of MENAINV -driven metastatic lesions. Mechanistically, MENA isoform expression alters the ratio of dynamic and stable microtubule populations in paclitaxel-treated cells. MENA expression also increases MAPK signaling in response to paclitaxel treatment. Decreasing ERK phosphorylation by cotreatment with MEK inhibitor restored paclitaxel sensitivity by driving microtubule stabilization in MENA isoform-expressing cells. Our results reveal a novel mechanism of taxane resistance in highly metastatic breast cancer cells and identify a combination therapy to overcome such resistance.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1158/1535-7163.MCT-16-0413
